Is Outlook Therapeutics, Inc. (OTLK) Halal?
Shariah Screening — 5 Standards
Based on financial data from September 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 87.8% / 30% | 23.5% / 30% | 4.3% / 30% | 6.35% / 5% | ✗ NOT HALAL |
| DJIM | 87.8% / 33% | 23.5% / 33% | 4.3% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| MSCI | 162.5% / 33% | 43.5% / 33% | 8.0% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| S&P | 87.8% / 33% | 23.5% / 33% | 4.3% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| FTSE | 162.5% / 33% | 43.5% / 33% | 8.0% / 50% | 6.35% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 1116.4% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -209.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$52M |
| Free Cash Flow | -$52M |
| Total Debt | $30M |
| Current Ratio | 0.3 |
| Total Assets | $19M |
Price & Trading
| Last Close | $0.21 |
| 50-Day MA | $0.42 |
| 200-Day MA | $1.31 |
| Avg Volume | 5.3M |
| Beta | -0.1 |
|
52-Week Range
$0.16
| |
About Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Outlook Therapeutics, Inc. (OTLK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Outlook Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Outlook Therapeutics, Inc.'s debt ratio?
Outlook Therapeutics, Inc.'s debt ratio is 87.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 162.5%.
What are Outlook Therapeutics, Inc.'s key financial metrics?
Outlook Therapeutics, Inc. has a market capitalization of $22M, and revenue of $1M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.